CP-012
Nocturnal immobility and morning akinesia in Parkinson's disease
Phase 1bActive
Key Facts
Indication
Nocturnal immobility and morning akinesia in Parkinson's disease
Phase
Phase 1b
Status
Active
Company
About Contera Pharma
Contera Pharma is a private, clinical-stage biotech company based in Hørsholm, Denmark, pioneering RNA-targeting therapeutics for neurological disorders. Its core asset is a proprietary discovery platform that integrates data for a precision medicine approach to identify and validate novel targets. The company has advanced its lead asset, CP-012 for Parkinson's disease, to Phase 1b with positive topline results, and is pursuing strategic partnerships, notably a 2025 research collaboration with Lundbeck, to expand its pipeline and accelerate development.
View full company profile